

Successful Treatment of Chemotherapy-induced Symptoms with Granisetron as Alternative for Ondansetron Allergy

Öner Özdemir¹, Olena Erkun²

¹Sakarya University Faculty of Medicine; Sakarya Training and Research Hospital, Department of Pediatrics, Division of Allergy and Immunology, Sakarya, Turkey

²Sakarya Training and Research Hospital, Clinic of Pediatrics, Sakarya, Turkey

Cite this article as: Özdemir Ö, Erkun O. Successful Treatment of Chemotherapy-induced Symptoms with Granisetron as Alternative for Ondansetron Allergy. J Acad Res Med 2021;11(2):227-9

ABSTRACT

Ondansetron is a selective 5-hydroxy-tryptamine 3 receptor antagonist that is widely used as an antiemetic agent, especially for the preventive treatment of chemotherapy-induced nausea and vomiting. Side effects of ondansetron are headache, dizziness, constipation, diarrhoea and hypersensitivity reactions such as anaphylaxis, which are very rarely described in the literature. Herein, we present a patient with Hodgkin lymphoma who developed urticaria secondary to ondansetron intake, had been receiving chemotherapy and has safely used granisetron as alternative. Granisetron appears to be a safer potent alternative to ondansetron in patients with cancer receiving chemotherapy.

Keywords: Hypersensitivity, urticaria, drug hypersensitivity, ondansetron, granisetron

INTRODUCTION

Ondansetron is a selective 5-hydroxy-tryptamine 3 (5-HT₃) receptor antagonist that is widely used in haematology and oncology wards. Ondansetron has highly antiemetic (anti-emetogenic) effect (1). Thus, ondansetron is often used for the prevention and treatment of chemotherapy-induced nausea and vomiting (1). Ondansetron has several common side effects, which include headache, dizziness, diarrhoea, fever and constipation (1). There were reports of electrocardiographic changes in some patients (2). However, IgE- or non-IgE-mediated hypersensitivity reactions such as urticaria, anaphylaxis and anaphylactoid reactions are very rarely reported side effects of ondansetron (3-7).

Herein, we present the case of a patient with Hodgkin lymphoma who developed urticaria following ondansetron intake and was

later successfully treated with granisetron for chemotherapy-induced nausea and vomiting.

CASE PRESENTATION

A 9-year-old boy was scheduled to undergo chemotherapy for nodular sclerosing Hodgkin lymphoma, which constitutes a combination of four drugs, namely, vinblastin, dacarbazine, doxorubicin and bleomycin, as well as ondansetron for prevention of nausea and vomiting. Within the last 6 months, the patient has been receiving chemotherapy and using ondansetron as prophylaxis for severe nausea. He had no known history of hypersensitivity reactions to any food and/or drug allergens, including ondansetron. During the intravenous administration of the first dose of ondansetron (0.15 mg/kg; total, 4 mg) at the last chemotherapy course, after 2-3 min, the patient developed redness (flare) and wheals along with urticaria (Figure 1). There

ORCID IDs of the authors: Ö.Ö. 0000-0002-5338-9561; O.E. 0000-0003-3067-3794.

Corresponding Author: Öner Özdemir,

E-mail: ozdemir_oner@hotmail.com



Received Date: 01.03.2021 **Accepted Date:** 25.06.2021

©Copyright 2021 by University of Health Sciences Turkey, Gaziosmanpaşa Training and Research Hospital. Available on-line at www.jarem.org

was no accompanying bronchospasm or hypotension. The patient was immediately treated with intravenous administration of 30 mg pheniramine (1 mg/kg). The reaction disappeared within a few minutes. The patient did not complain of any other symptoms and was discharged after a couple of hours of observation. He was asymptomatic within 24 h of follow-up.

According to the patient's mother, during the past one session of chemotherapy, the patient also demonstrated redness, swelling and mild rash over the body after injection of ondansetron. The patient has no individual or family history of atopy and asthma, but he has a history of common variable immunodeficiency disease. Thus, he has been receiving intravenous treatment with immunoglobulin.

After allergy consultation, the skin prick test to undiluted ondansetron (2 mg/mL concentration) with commercial product was performed, and the result was negative. Moreover, intradermal test showed a positive response to 0.02 mg/mL (100 times dilution of ondansetron) concentration, and a positive flare and wheal reaction were observed (hyperaemia, 35 mm; wheal, 20 mm) (Figure 2). Because of this positive response, intradermal test to 10 times dilution of ondansetron was not performed. Furthermore, the skin prick test and intradermal tests with an alternative drug granisetron (1 mg/mL, undiluted) were performed similarly for granisetron (1:100 and 1:10 dilution), and all test results were negative. The prick and intradermal test concentrations for both ondansetron and granisetron were defined based on previous clinical reports (5,8). All skin prick and intradermal tests were performed with original commercial preparations including

excipients. Since our patient needed one of the 5-HT₃ receptor antagonists, we provoked him the same day with granisetron as an alternative. He was given intravenously cumulative doses of granisetron at 20-min intervals under strict scrutiny, beginning with 1 mg up to the therapy dose of 100 mg, as described earlier (9). As a result, granisetron was successfully administered to the patient for prevention of chemotherapy-induced nausea and vomiting.

Verbal and written informed consents were obtained from the patient's parents for publication of this case report and any accompanying images.

DISCUSSION

The 5-HT₃ receptor antagonists (ondansetron, tropisetron, granisetron, dolasetron and palonosetron) are well-tolerated, potent antiemetic drugs that are used for the prevention of chemotherapy-induced nausea and vomiting. They are highly safe and have rare side effects, such as dizziness, headache, dystonia, constipation, chest pain and prolongation of the QT period on electrocardiogram (1,2). In our case, the side effect was a localised urticarial wheal near the injection site. It was successfully treated with administration of antihistaminic drug without any need of further medications such as epinephrine and/or prednisolone.

In the literature, hypersensitivity reaction induced by ondansetron has been reported in patients with cancer, who are undergoing chemotherapy with a prior history of ondansetron exposure (3-10). However, some authors hypothesise that hypersensitivity may be a class effect, while some others suggest that it is drug-specific effect as long as ondansetron and tropisetron contain indole



Figure 1. Redness and wheals after administration of ondansetron



Figure 2. Positive result to intradermal test with 0.02 mg/mL (100 times dilution) of ondansetron (hyperaemia, 35 mm; wheal, 20 mm)

ring, whereas granisetron does not (5). Thereby, some authors advise avoidance of all 5-HT₃ antagonists after developing hypersensitivity to ondansetron. Others have demonstrated the successful utilisation of granisetron (9,10).

Before giving a substitute drug to a patient with drug allergy, it is compulsory to first learn possible cross-reactivity by performing skin tests and provocation tests (6). Granisetron might be an alternative antiemetic agent for patients with cancer who are undergoing chemotherapy (9,10).

In conclusion, we describe a rare case of IgE-mediated type I hypersensitivity to ondansetron that presents as isolated urticaria (9). In consistent with the literature, granisetron can be considered a safer potent alternative to ondansetron in patients with cancer who are receiving chemotherapy.

Informed Consent: Verbal and written informed consents were obtained from the patient's parents for publication of this case report and any accompanying images.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - Ö.Ö., O.E.; Design - Ö.Ö., O.E.; Data Collection and/or Processing - Ö.Ö., O.E.; Analysis and/or Interpretation - Ö.Ö.; Literature Search - O.E.; Writing - Ö.Ö., O.E.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

1. Chaudhary NK, John RR, Boddu D, Mahasampath G, Nesadeepam N, Mathew LG. Palonosetron is a better choice compared with ondansetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in a resource-limited pediatric oncology center: results from a randomized control trial. *J Pediatr Hematol Oncol* 2019; 41: 294-7.
2. Krammes SK, Jacobs T, Clark JM, Lutes RE. Effect of intravenous ondansetron on the QT interval of patients' electrocardiograms. *Pediatr Emerg Care* 2018; 34: 38-41.
3. Kataja V, de Bruijn KM. Hypersensitivity reactions associated with 5-hydroxytryptamine (3)-receptor antagonists: a class effect? *Lancet* 1996; 2: 584-5.
4. Mehra KK, Gogtay NJ, Ainchwar R, Bichile LS. Hypersensitivity to intravenous ondansetron: a case report. *J Med Case Rep* 2008; 2: 274.
5. García Núñez I, Algaba Mármol MA, Reina Ariza E. Ondansetron hypersensitivity: a clinical diagnosis protocol and cross-reactivity study. *J Investig Allergol Clin Immunol* 2015; 25: 221-2.
6. Ross AK, Ferrero-Conover D. Anaphylactoid reaction due to the administration of ondansetron in a pediatric neurosurgical patient. *Anesth Analg* 1998; 87: 779-80.
7. Weiss KS. Anaphylactic reaction to ondansetron. *Arch Intern Med* 2001; 161: 2263.
8. Fernando SL, Broadfoot AJ. Ondansetron anaphylaxis: a case report and protocol for skin testing. *J Med Case Rep* 2009; 102: 285-6.
9. Bousquet PJ, Co-Minh HB, Demoly P. Isolated urticaria to ondansetron and successful treatment with granisetron. *Allergy* 2005; 60: 543-4.
10. Demir AH. Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report. *J Pediatr Hematol Oncol* 2010; 32: e341-2.